Latest Research
All publications from the Cancer3.AI database, newest first.
Angiomatous Subtype of Penile Kaposi Sarcoma With Concurrent HIV-Negative Multicentric Castleman Disease: A Case Report.
Vashisht T, et al
This case report describes an exceptionally rare presentation of Kaposi sarcoma in a 58-year-old HIV-negative man who also had HHV-8-associated multicentric Castleman disease, a lymph node disorder linked to the same virus. The patient developed skin lesions on the buttock and an ulcerated lesion on the penile shaft, which on biopsy showed an unusual angiomatous subtype of Kaposi sarcoma lacking the typical spindle-cell appearance seen in classic cases. Specialized immunohistochemical staining confirmed positivity for HHV-8 and vascular markers including PDPN, CD34, and ERG, supporting the diagnosis despite the atypical morphology. Despite aggressive treatment, the patient deteriorated rapidly and died from multiorgan failure. This case highlights that Kaposi sarcoma can occur without HIV infection in the context of multicentric Castleman disease, and that its angiomatous subtype may be misdiagnosed if clinicians are not aware of its distinct histological features. Recognizing this rare combination is critical for timely diagnosis and management, particularly when unusual anatomical sites such as the penis are involved.
International journal of surgical pathology
Source →Relative survival analysis of dermatofibrosarcoma protuberans, Kaposi sarcoma, and pleomorphic sarcoma across intersectional demographics: A Surveillance, Epidemiology, and End Results (SEER) study.
Hu BD, et al
A new study published in the Journal of the American Academy of Dermatology used data from the Surveillance, Epidemiology, and End Results (SEER) program to examine how patients with three rare skin and soft-tissue cancers — dermatofibrosarcoma protuberans (DFSP), Kaposi sarcoma, and pleomorphic sarcoma — survive relative to the general population. The researchers applied an intersectional demographic approach, meaning they analyzed how combinations of factors such as race, sex, and age simultaneously influence survival outcomes, rather than considering each variable in isolation. The findings reveal meaningful disparities in relative survival across demographic groups, suggesting that certain populations face compounding disadvantages in cancer outcomes that are not captured by single-variable analyses. These results highlight the importance of intersectionality in oncology research and underscore the need for targeted clinical attention and equitable resource allocation for underserved groups diagnosed with these uncommon malignancies. For clinicians, the study provides a more nuanced picture of prognosis that can inform patient counseling and guide efforts to reduce survival gaps in dermatologic cancers.
Journal of the American Academy of Dermatology
Source →A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma.
Lim M, et al
Researchers at MD Anderson Cancer Center conducted the largest retrospective study to date examining taxane-based chemotherapy in patients with small bowel adenocarcinoma (SBA), a rare cancer that is molecularly distinct from more common gastrointestinal cancers but often treated similarly to colorectal cancer. The study analyzed 70 SBA patients treated between 1994 and 2024, finding an overall response rate of 24%, a median time to progression of 3.1 months, and a median overall survival of 8.7 months, suggesting taxanes have meaningful but limited activity in this disease. A key discovery was that patients whose tumors carried a TP53 mutation — present in 63% of cases — responded significantly worse to taxane therapy, with a response rate of only 20% compared to 45% in patients with normal TP53, and notably shorter survival. These findings position TP53 mutation status as a potential negative predictive biomarker that could help oncologists select which SBA patients are most likely to benefit from taxane-based treatment. The results are particularly important given the scarcity of evidence-based treatment options for SBA, a disease that has historically been managed by borrowing protocols from colorectal cancer despite important biological differences. The authors conclude that these results support the design of prospective clinical trials specifically targeting metastatic SBA.
The oncologist
Source →[Colorectal cancer recurrence].
Ravn S, et al
A new review published in Ugeskrift for laeger examines the significant challenge of colorectal cancer recurrence, which affects approximately 16% of patients within five years following curative surgery and is associated with high mortality rates. The review highlights that early spread of cancer cells and a phenomenon known as tumor dormancy make timely detection of recurrence particularly difficult. Recurrences most commonly appear in the liver, lungs, or peritoneum, and current follow-up strategies aim to catch these early, though the survival benefits of such surveillance remain uncertain. Encouragingly, around half of patients who experience recurrence may still be eligible for curative treatment, typically involving surgery or chemotherapy. The authors conclude that further research is urgently needed to develop better strategies for improving outcomes in this vulnerable patient population.
Ugeskrift for laeger
Source →Rare Rectal Involvement of Metastatic Appendiceal Adenocarcinoma Mimicking Primary Rectal Cancer.
Aboulhamid N, et al
Researchers report an exceptionally rare case of a 44-year-old man whose appendiceal adenocarcinoma spread to the rectum, a metastatic pattern virtually unseen in medical literature. Sixteen months after undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for his original diagnosis, the patient developed constipation and tenesmus, prompting colonoscopy that revealed a large ulcerated rectal mass. Tissue analysis and immunoprofiling confirmed the mass as poorly differentiated adenocarcinoma consistent with appendiceal origin, distinguished from primary rectal cancer by a specific protein marker pattern. To the authors' knowledge, this is only the second documented case of rectal metastasis from appendiceal cancer ever reported, and the first to propose a possible mechanism by which cancer cells may travel from the appendix to the rectum. This case highlights the importance of thorough clinical history and advanced tissue testing when evaluating rectal masses in patients with prior gastrointestinal cancers, as metastatic lesions can closely mimic primary rectal tumors. Clinicians should consider rare metastatic patterns when managing appendiceal cancer survivors presenting with new colorectal symptoms.
ACG case reports journal
Source →